Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
ACS Chem Neurosci
2019 Nov 20;1011:4716-4728. doi: 10.1021/acschemneuro.9b00484.
Show Gene links
Show Anatomy links
Azi-medetomidine: Synthesis and Characterization of a Novel α2 Adrenergic Photoaffinity Ligand.
McKinstry-Wu AR
,
Woll KA
,
Joseph TT
,
Bu W
,
White ER
,
Bhanu NV
,
Garcia BA
,
Brannigan G
,
Dailey WP
,
Eckenhoff RG
.
???displayArticle.abstract???
Agonists at the α2 adrenergic receptor produce sedation, increase focus, provide analgesia, and induce centrally mediated hypotension and bradycardia, yet neither their dynamic interactions with adrenergic receptors nor their modulation of neuronal circuit activity is completely understood. Photoaffinity ligands of α2 adrenergic agonists have the potential both to capture discrete moments of ligand-receptor interactions and to prolong naturalistic drug effects in discrete regions of tissue in vivo. We present here the synthesis and characterization of a novel α2 adrenergic agonist photolabel based on the imidazole medetomidine called azi-medetomidine. Azi-medetomidine shares protein association characteristics with its parent compound in experimental model systems and by molecular dynamics simulation of interactions with the α2A adrenergic receptor. Azi-medetomidine acts as an agonist at α2A adrenergic receptors, and produces hypnosis in Xenopus laevis tadpoles. Azi-medetomidine competes with the α2 agonist clonidine at α2A adrenergic receptors, which is potentiated by photolabeling, and azi-medetomidine labels moieties on the α2A adrenergic receptor as determined by mass spectrometry in a manner consistent with a simulated model. This novel α2 adrenergic agonist photolabel can serve as a powerful tool for in vitro and in vivo investigations of adrenergic signaling.
Amemiya,
Synthesis and alpha-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogues.
1992, Pubmed
Amemiya,
Synthesis and alpha-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogues.
1992,
Pubmed
Best,
Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles.
2012,
Pubmed
Bhattacharya,
Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures.
2000,
Pubmed
Chung,
Conformational changes in the G protein Gs induced by the β2 adrenergic receptor.
2011,
Pubmed
Correa-Sales,
A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats.
1992,
Pubmed
Ebert,
The effects of increasing plasma concentrations of dexmedetomidine in humans.
2000,
Pubmed
Eckenhoff,
Amino acid resolution of halothane binding sites in serum albumin.
1996,
Pubmed
Fiser,
Modeling of loops in protein structures.
2000,
Pubmed
Frang,
Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors.
2001,
Pubmed
Gilsbach,
Genetic dissection of alpha2-adrenoceptor functions in adrenergic versus nonadrenergic cells.
2009,
Pubmed
Jasper,
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.
1998,
Pubmed
Jo,
CHARMM-GUI: a web-based graphical user interface for CHARMM.
2008,
Pubmed
Jo,
CHARMM-GUI Membrane Builder for mixed bilayers and its application to yeast membranes.
2009,
Pubmed
Karlsson,
Characterization of pigment aggregating alpha 2-adrenoceptors of fish melanophores by use of different agonists after partial irreversible receptor inactivation.
1989,
Pubmed
Klauda,
Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types.
2010,
Pubmed
Lakhlani,
Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo.
1997,
Pubmed
Marjamaki,
Chloroethylclonidine binds irreversibly to exposed cysteines in the fifth membrane-spanning domain of the human alpha2A-adrenergic receptor.
1998,
Pubmed
Marjamäki,
Chloroethylclonidine and 2-aminoethyl methanethiosulfonate recognize two different conformations of the human alpha(2A)-adrenergic receptor.
1999,
Pubmed
Marín,
Do amphibians have a true locus coeruleus?
1996,
Pubmed
Masureel,
Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist.
2018,
Pubmed
McKinstry-Wu,
Optoanesthesia: Use of Anesthetic Photolabels In Vivo.
2018,
Pubmed
Nelson,
The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects.
2003,
Pubmed
Paris,
The anesthetic effects of etomidate: species-specific interaction with alpha 2-adrenoceptors.
2007,
Pubmed
,
Xenbase
Peltonen,
Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor.
2003,
Pubmed
Phillips,
Scalable molecular dynamics with NAMD.
2005,
Pubmed
Rasmussen,
Structure of a nanobody-stabilized active state of the β(2) adrenoceptor.
2011,
Pubmed
Ruuskanen,
Identification of duplicated fourth alpha2-adrenergic receptor subtype by cloning and mapping of five receptor genes in zebrafish.
2004,
Pubmed
Ruuskanen,
Expression and function of alpha-adrenoceptors in zebrafish: drug effects, mRNA and receptor distributions.
2005,
Pubmed
Salminen,
Three-dimensional models of alpha(2A)-adrenergic receptor complexes provide a structural explanation for ligand binding.
1999,
Pubmed
Sand,
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics.
2014,
Pubmed
Savola,
Central alpha 2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine.
1991,
Pubmed
Scheinin,
Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers.
1998,
Pubmed
Smeets,
Catecholamine systems in the brain of vertebrates: new perspectives through a comparative approach.
2000,
Pubmed
Stewart,
p-(4-Azipentyl)propofol: a potent photoreactive general anesthetic derivative of propofol.
2011,
Pubmed
,
Xenbase
Tonner,
Inhibition of nitric oxide metabolism enhances the hypnotic-anesthetic action of the alpha2-adrenoceptor agonist dexmedetomidine in vivo.
1999,
Pubmed
,
Xenbase
Trott,
AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.
2010,
Pubmed
Voigt,
Asymmetrically modified nucleosomes.
2012,
Pubmed
Warne,
Molecular basis for high-affinity agonist binding in GPCRs.
2019,
Pubmed
Weiser,
In vivo activation of azipropofol prolongs anesthesia and reveals synaptic targets.
2013,
Pubmed
,
Xenbase
Woll,
A Novel Bifunctional Alkylphenol Anesthetic Allows Characterization of γ-Aminobutyric Acid, Type A (GABAA), Receptor Subunit Binding Selectivity in Synaptosomes.
2016,
Pubmed
Woll,
Sites Contributing to TRPA1 Activation by the Anesthetic Propofol Identified by Photoaffinity Labeling.
2017,
Pubmed
Yip,
A propofol binding site on mammalian GABAA receptors identified by photolabeling.
2013,
Pubmed
Zhang,
Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potential binding interactions with alpha 2-adrenoceptors involving a "methyl pocket".
1997,
Pubmed
Zhang,
Neuronal ensembles sufficient for recovery sleep and the sedative actions of α2 adrenergic agonists.
2015,
Pubmed
